Physician profile
Matthew Luxenberg
NPI 1548353121
$10,591.20
in general payments reported to CMS, 2019-2025
21 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $648 · 2021: $847 · 2022: $814 · 2023: $1,500 · 2024: $4,006 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,751.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,935.64 | 2024 | M22 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,502.98 | 2019-2025 | Siliq, Targretin, Duobrii |
| Dermavant Sciences, INC. | $1,111.82 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $897.15 | 2021-2023 | Winlevi, Absorica Ld, Ilumya |
| Medimetriks Pharmaceuticals, INC. | $776.98 | 2019-2022 | |
| Abbvie INC. | $727.06 | 2022-2025 | |
| Prugen, INC. Pharmaceuticals | $584.59 | 2019 | |
| Ucb, INC. | $505.71 | 2024-2025 | Bimzelx |
| Amgen INC. | $428.67 | 2023-2025 | Otezla, Amjevita, Otezla |
| Incyte Corporation | $421.54 | 2023-2025 | Opzelura |
| Almirall LLC | $372.43 | 2019-2020 | |
| Lilly USA, LLC | $335.11 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.05 | 2025 | Siliq, Xifaxan |
| Arcutis Biotherapeutics, INC. | $206.61 | 2024 | Zoryve |
| Pfizer INC. | $201.98 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $197.47 | 2023-2025 | Nemluvio, Dysport |
| E.R. Squibb & Sons, L.L.C. | $64.36 | 2023-2024 | Sotyktu |
| Smith+Nephew, INC. | $44.90 | 2021-2023 | Renasys Go V2 Home |
| Revance Therapeutics, INC. | $30.00 | 2025 | Daxxify |
| Janssen Biotech, INC. | $29.39 | 2025 | Tremfya, Stelara, Simponi |
| Organon LLC | $4.76 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Luxenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.